Use of recombinant granulocyte-macrophage colony stimulating factor in the Brazil radiation accident

Lancet. 1988 Aug 27;2(8609):471-5. doi: 10.1016/s0140-6736(88)90121-3.

Abstract

8 patients with bone marrow failure after a caesium-137 radiation accident were treated with recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF). The 7 who were evaluable had prompt increases in granulocytes and bone marrow cellularity. 2 patients died of radiation toxicity and haemorrhage and 2 of bacterial sepsis acquired before the start of rHuGM-CSF treatment. 4 patients survive, including 2 who were treated early and never became infected. This therapeutic approach to radiation-induced granulocytopenia may therefore be useful after radiation and nuclear accidents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Accidents*
  • Acute Disease
  • Adolescent
  • Adult
  • Agranulocytosis / drug therapy*
  • Agranulocytosis / etiology
  • Agranulocytosis / mortality
  • Brazil
  • Cesium Radioisotopes / adverse effects*
  • Child
  • Colony-Stimulating Factors / adverse effects
  • Colony-Stimulating Factors / therapeutic use*
  • Drug Evaluation
  • Environmental Exposure
  • Equipment Contamination
  • Female
  • Food Contamination, Radioactive
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Growth Substances / adverse effects
  • Growth Substances / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Radiation Dosage
  • Radiation Injuries / drug therapy*
  • Radiation Injuries / etiology
  • Radiation Injuries / mortality
  • Radioactive Waste / adverse effects
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Time Factors

Substances

  • Cesium Radioisotopes
  • Colony-Stimulating Factors
  • Growth Substances
  • Radioactive Waste
  • Recombinant Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor